Tocilizumab for severe COVID-19: Review and meta-analysis

Noor Hadi Farhan[1]; Rasha A. Abidalmutalib Aljabawi[1]; Ammar F. al- tumaa[1]

noor.h@uokerbala.edu.iq

rasha.aziz@uokerbala.edu.iq

ammar.f@uokerbala.edu.iq

[1] clinical laboratory science department, Pharmacy College; University of Karbala, Iraq

Abstract

COVID-19 had been a worldwide epidemic infectious disease since March 2020, when it first spread and then deteriorated. Efforts were focused on enlisting the help of the scientific community to stop the sickness from spreading and find a cure. Although the fact that vaccination is an important aspect of the public health plan for reducing COVID-19's impact, the pandemic's management will continue to rely on pharmacological therapy. Approximately, 3 quarters of COVID-19 individual patients in critical situations preceded with Interleukin-6 associated with failure of respiratory system. Interleukin-6 concentration is a trustworthy predictor about the severity of infection due to the remarkable elevation in mortality cases and considered as a promised target for pharmacological drugs like tocilizumab, which is an interleukin receptor blocker that has been administered off label use accompanied with treatment results in Taking care of patients with serious illnesses. The objective of this research is to provide an updated review to evaluate the effect of tucilizumab, an interlukin receptor blocker on fatality rates for cases with critical COVID 19 conditions. PubMed, Google Scholar, and other scientific databases and centers were used to perform the research for studies reporting results for hospitalized patient treated with tucilizumab compared with control patients (treated with conventional therapy) and moratality rate percent were conducted. A total of 5630 patients (10 studies; n= 1219 received TCZ; n=4411 control patients received conventional therapy) with severe COVID- 19 conditions. Outcomes was improved with TCZ (28.3% mortality rate) compared with 40.98% in control patients.Based on the findings of this research, we can infer that administering TCZ to patients with severe COVID-19 reduces the risk of mortality.

Keywords: **COVID 19**; **tucilizumab; mortality rate, interlukin-6 inhibitor**

نبذة مختصرة

منذ اندلاع كوفيد -١٩ والإعلان اللاحق له باعتباره وباءً عالميًا في مارس 2020 ، بذل المجتمع العلمي جهودًا متضافرة للسيطرة على انتشار المرض وإيجاد علاج. بينما تشكل اللقاحات جزءًا حيويًا من استراتيجية الصحة العامة لتقليل عبء كوفيد ١٩. ستستمر معالجة هذا المرض بالاعتماد على العلاج الدوائي. ما يقرب من ثلاثة أرباع المرضى الذين يعانون من حالة خطيرة يعانون من فشل تنفسي بوساطة انترلوكين ٦ . يعد تركيز انترلوكين ٦مؤشراً موثوقًا على شدة كوفيد ١٩_نظرًا لارتفاعه بشكل كبير في الحالات المميتة. ويعتبر هدفًا واعدًا لعقاقير مثل tocilizumab، وهو مضاد لمستقبلات الإنترلوكين تم استخدامه بشكل غير مصادق عليه مع نتائج علاجية مختلفة لعلاج الحالات الشديدة. تهدف هذه الدراسة إلى تقديم مراجعة محدثة لتقييم تأثير (TCZ) tocilizumab وهو مضاد لمستقبلات الإنترلوكين على معدل الوفيات للمرضى المصابين بفيروس كوفيد -19 الحاد. تم إجراء هذه المراجعة و الدراسة باستخدام قواعد بيانات PubMed، Google Scholar ومواقع بحثية اخرى للدراسات التي تشير إلى نتائج للمرضى المقيمين في المستشفى الذين عولجوا ب tocilizumab مقارنة بمرضى الكوفيد 19 (الذين عولجوا بالعلاج التقليدي) وأجريت النسبة المئوية لمعدل الوفيات. مجموعة متكونه من5630 مريضا (10 دراسات ؛ العدد = 1219 تلقوا TCZ , نسبة الذكور (67.6%) ومتوسط العمر60.9 سنة؛ العدد = 4411 من مرضى الجائحة تلقوا العلاج التقليدي , نسبة الذكور 70.9%) ومتوسط العمر 63.6 سنة) مع حالات COVID- 19الشديدة تم تحسين النتائج باستخدام TCZ(معدل الوفيات 28.3٪) مقارنة بـ 40.98٪ من مرضى الجائحة. بناءً على نتائج هذه المراجعة ، يمكننا أن نستنتج أن إعطاء TCZمن شأنه أن يقلل من خطر معدل الوفيات لدى المرضى المصابين بـ COVID-19الشديد.

الكلمات المفتاحية : كوفيد-١٩ ، tocillizumab ، معدل الوفيات , مضاد انترلوكين-6

Introduction

Coronavirus infections (COVID-19) is a viral condition induced severe acute respiratory distress syndrome Corona Virus 2 [SARS- CoV-2] and was first reported in December 2019 in Wuhan, China [1] . It has been induced significant critical conditions on the subject of public health through an extreme rise in the rates of morbidity & mortality all throughout the globe. The majority of infected individuals will stay with no symptoms or develop minor symptoms, but approximately 20% of infected patients has been developed a serious pneumonic condition in addition to Acute Respiratory Distressing Syndrome [ARDS], which can escalate to form cytokine storming and induce complete organ damage [2] . Furthermore, Drugs like Remdesivir, Bamlanivimab and dexamethasone have been prescribed by the US Food and Drug Administration [US FDA] for the management of COVID-19 in inpatients cases . While drugs such as decitabine, infliximab and duvelisib [3] are recently COVID-19 is now in the clinical development phase. Interleukin-6 (IL-6) is well known as a multifunctional cytokine that play a key role in immunological homeostasis, inflammation, and infection in this environment [4] . Elevation of IL-6 level in blood has significant correlation with rates of death for patients with covid-19 infection . IL-6 amplifier activation cause induction of storm of cytokines, as a sign of inflammatory dysregulation. As a result, inhibiting or blockage the Interlukin-6 amplification, alleviated the storming of cytokines that caused by covid-19 infection. At these aspects many researcher studies had disclosed that Tucilizumab (Tcz) treatment could help COVID-19 infected patients' health by enhancing the respiratory functions, decreasing C-Reactive Protein levels, and improving the health deteriorations due to corona virus infection [5]

In the light of this, review has been conducted to assess the therapeutic advantages of tucilizumab administration as a single or in conjunction with standard of care [SOC] and/or placebo in lowering fatality rates provoked by COVID-19.

1.1 Coronaviruses

Coronaviruses considered as enclosed RNA viruses that distinctly profound in people and animals. They belonged to Nidovirales order that included other families like Roniviridae, Arteriviridae [6] . Viruses had virus-related RNA genome that measured dimension from 26 to 32 kilo-bases, and this made them possible to isolate themselves from different animal species. Furthermore, coronaviruses can be observed under electron microscope possessing a crown-like appearance. The extensive spread of this virus accompanied with critical health risks made them essential pathogenic disease [7]. COVID-19 is recently discovering Strain of coronavirus. The viral RNA is liberated when the virus penetrate the cell, and polyproteins then translated from genomic RNA. The transcripted and replicated process occur by cleaving protein that assemble of the complex replicase–transcriptase. After RNA viral replication then structural proteins synthesis; viral particles are formed and packaged in an infected cell, and subsequently discharged [8].These proteins could be used as therapeutic targets in the future [9]

The protein of SARS-CoV-2 S is involved in receptor identification, viral adhesion, and invasion into infected cell. A virus must initially gain access to a cell in order to distribute. Perforating a cell's periphery, on the other hand, is challenging. Cells' exterior membranes are generally difficult to penetrate without a unique approach. Virus had tactics of deceiving cells to letting them access, but most of the time, a component of virus's cloaking has a great affinity for binding to proteins that dot the membranes of many cells types. The virus's attachment to that cell-surface protein serve as an admittance pass, making it easier to invade the cell. inside cell, Viral polymerases build many replicas of the attacker's genomes, which the cell obeying the molecular production system uses to make capsid components and also other proteins. then taken over by the virus . For export, newer replicas arehave been wrapped into newly formed capsids [10]

1.1.1 Mechanism of action of Covid _19

The coronavirus's external surface glycoprotein spikes are important for the virus's adhesion and entry into invaded cells. virus's receptor-binding domain (RBD) is frequently elatedr, allowing it to infect a variety of individuals [11]. Cellular proteolytic enzymes including such human airway trypsin-like protease [HAT], transmembrane protease serine 2 [TMPRSS2] and cathepsin, which cleave the spiking peptide and produce further penetrating changes, are required for coronavirus entrance [12,13]. Dipeptidyl peptidase 4 (DPP4) is a key receptor for MERS-coronavirus, while Angiotensin Converting Enzyme 2 (ACE2) is used by SARS-coronavirus . The spiking proteins does have a three dimensional structures in the RBD region to maintain van

der Waals forces. The 394 glutamine is recognized by the critical lysine 31 residue on the human ACE2 receptor. [14]

1.1.2 COVID-19 Infections and Their Severity

The intensity of adult infected cases is categorized into the following categories. Clinical guidelines and clinical studies may have overlapping or differing criteria for each category, and individual that could alter in the long term..

a) Infection that is asymptomatic/pre-symptomatic: Those whom screened positive with Middle east respiratory syndrome on a virologic test (such as a polymerase chain reaction or antigen assay) with no symptoms similar to COVID-19 showing yet.

b) the mild illness: A light condition is defined as someone who experience one or more of COVID-19 clinical manifestations (coughing, sores, exhaustion, headaches, muscles aches, nauseous, vomit, diarrhoea, lack of flavor and aroma) and yet no difficulty breathing, distress, or abnormal lung radiography..

.**c) Moderate Illness**: Individuals who have a level of oxygen saturation of 94 percent and show indications of reduce respiratory function when performing clinical examination or scan imaging.

d) Serious illness: Patients with an arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio of less than 300 mmHg, respiratory frequency greater than 30 breaths per minute or lung infiltration greater than 50%.

e) the life threatening category: People that are suffering from arrest of respiratory system, septicemia in addition to malfunction of many organs [15].

1.1.3 Covid-19 infection triggers immune responses

Even after the viral load drops, serious conditions defined by immune response dysregulation, which has been linked to disease mortality[16] . Both immunological disorder and the symptom exacerbation are caused by two consecutive and diametrically opposing reactions. The first pattern is lymphocytopenia, which is characterized by a T-cells, B-cells, and natural killer (NK) cells have all shown a considerable decline in addition to CD4+ and CD8+ T cells. While all COVID-19 patients have a large decrease in T cells, severe cases have a greater decline in B and NK cells[17] . The abilities of body remove virus then moderate the inflammation reaction is harmed by adaptive immune cell reduction. Overactivation of the body own immune system considered the second harmful response. Raised the neutrophil level and cytokines such as IL 6,

IL 1, IL 2, IL 8, CCL3, and TNF characterize this pathogenic response. Septeciemia, cells destruction, and malfunction of many organs are all caused by rapidly rising the level of cytokine, often recognized as a cytokines storm (heart, liver, kidney, respiratory*)* [17].Interleukin_6 concentration considered as a solid estimator of how COVID-19 is serious illness. Hematopoietic, metabolic control, inflammatory process, autoimmunity, and the response of acute phase are all influenced by IL-6 [18]. IL-6-dependent effects include directing neutrophil migration to the infection site, enhancing the cytolysis ability of CD8+ T cell, modulating the thermostatic reaction as antiviral effect outcomes that help fight infections. IL-6, on the other hand, is linked to the course of viral infection sickness because it causes permeable tissue and fluid retention, decreases the production of interferon, promotes the anti-apoptotic action of molecules, and supports survival by excess neutrophil. The aforementioned side effect cause fatal inflammatory response and allow virus penetration into distant tissues [19]. Furthermore, increased serum IL-6 is linked to decreased NK cell cytotoxic activity, reducing the ability to kill virus. Because interlukin 6 has been shown by enhancing the frequency with which fibrotic clots form. It's possible that it's contributing to the thrombotic problems seen with corona infection. Another significant element in IL-6 regulation and COVID-19 disease is Angiotensin Renin pathway, which regulates the blood pressure and balancing electrolyte. Because AcE2 bounded by virus, limiting availability, angiotensin II levels rise in patients with covid infection, resulting in loop of positive feedback which promotes signaling that trigger inflammation [20].

1.2 COVID-19 therapies

1.2.1 Antivirals

Without a specific medicine to address COVID-19's fatal immunological effects, scientists and physicians are scrambling to find other therapies and remedies [21]. A method is using an existing medication of antiviral effect in hopes that it will have the same effect on SARS-CoV-2. The remdesivir drug that inhibit RNA-dependent polymerase, lower death rate although it’s less benefit in serious instances, is one of the more promising treatments [22] . Antivirals such as hydroxychloroquine and chloroquine are also often utilized. Despite its antiviral and immunomodulatory properties in vitro and in vivo activities, data for the therapeutic effectiveness and preventive qualities of hydroxychloroquine or chloroquine for COVID-19 patients is insufficient [23].

1.2.2 immunosuppressive drugs

To offset the dysregulated, overactive immune response, various studies of possible immunological dampening and therapies that target cytokines have been conducted. Despite early data and warnings against the use of corticosteroids to treat severe COVID-19, a major randomization review analysis of dexamethasone indicated that the medicine substantially lowered 28-day deaths in individuals enrolled in the research [24]. However, death rate decreases differed based on initial respiration requirements at enrollment, based on initial respiratory demands at enrollment, with a reductions for those who use ventilatory support and oxygenation, yet not for those who don't [25]. The World Health Organization (WHO) changed their guideline against corticosteroids to allow for cautious use in patients with ARDS who are experiencing respiratory. More methods for tailored immune modulation are needed due to the systemic effects of corticosteroids. TNF, IFN, and IL-6 which is cytokine from the interlukins family (IL-1 and IL-18) are all common targets for suppression. Because of its link to ARDS severity and mortality, interlukien-6 is a significantly attractive goal therapy . Unfavorable T-cell treatment reactions, have already been successfully treated with IL-6 inhibitors [26]. Because of suppressing the viral replicating process, InterLukien-6 inhibitors should be cautiously provided with optimal timing in COVID-19 [27] .

[Actemra] tocilizumab is a humanized murine variable domain and human IgG1 constant domain synthetic monoclonal antibody which suppresses IL-6 generation. TCZ attaches to the IL-6 receptors located as well as those that are soluble, inhibiting IL-6 involved in signal transduction. (Fig. 1). The medication was first approved to treat rheumatoid arthritis, but it is now also approved to cure autoimmune disorders like giant cell arteritis its therapeutic value was investigated, and it has been discovered to be efficient in other cases, such as mediated by t immunotherapy, for the treatment of serious cytokine release crisis [18].

1.2.3 Tocilizumab's mechanism of action

The interlukin6 chemokine involved with hematogenesis, acute inflammatory reactivity, and immunological responses like the activation of T cell and the immunoglobulin release. It is made up of T and B lymphocytes, macrophages, fibroblast, and other components make it. Highly synthesis of IL-6 has been linked to diseases including multiple myeloma and rheumatoid arthritis. In individuals with SARS and COVID-19, circulating IL-6 levels are elevated. Excessive signaling from IL-6 triggers a cascade Janus kinases (JAK), which also has a multitude of consequences that

lead to damaging organ, including growing naive T cell becoming T lymphocyte, promoting VEGF production in the epithelial cells, raising vascular permeability, and lowering the cardiac contractility Tocilizumab was developed by grafted the complementary determining domains from IL-6R antibodies of mice upon humans IgG1, resulting in a humans interlukin6 receptor binding sites on the human antibodies [26]. On the surface of target cells IL-6 signal transduction is mediated by a ligand-binding IL-6R and a non-ligand-binding but signal-transducing chain, gp130. Signal transduction is also possible with soluble versions present in the blood and synovial fluids Tocilizumab identifies the binding sites of interlukin6 on its membranous and the soluble variants and which competitively inhibited the IL-6 binding to its receptor utilizing the conventional tocilizumab dose regimen [27]. Tocilizumab is indeed a monoclonal antibody which blocks the activation of activating complex with transmembrane protein [gp130-IL-6-sIL] by interfering with IL-6 receptors on both soluble and membraned sites. Tcz. can block the IL-6 trans-signal 46, that is linked to IL-6's pro-inflammation [28]. Interleukin 6 (IL-6) is involved in the development of immunological and inflammatory reactions, among other things. IL-6 levels are unusually high in several autoimmune disorders, such as RA. Tocilizumab binds both soluble and membrane-bound interleukin-6 receptors, preventing IL-6 from causing inflammation [29]



Fig.(1) Interlukin6 cascade associated with Tucilizumab inhibiting effect. Exposing to COVID 19 inducing the immunological cells (mainly the macrophage) to release the chemokine's specially the interlukien6 which may attached to a specific cell receptor of IL6R or a soluble cell receptor SIL6R that cause activation of JAK/STAT and NF-KB Pathways result in induction of the cytokines storm. Tucilizumab antibodies can crosslink of both interlukin-6 receptors to cut the transduction of signals and decrease chances of forming cytokines storm [18]

2. Methodology

2.1 Search strategy

The major search keywords for the inspection comprised 'COVID-19' or 'SARS-CoV-2' and 'tocilizumab' This data synthesis included papers with primary information for a case-control study comparing fatality rates from severe COVID-19 between TCZ and critical care unit with other treatments

2.2 Criteria's for inclusion

Those trials that specifically reported at least one of the outcome variables, particularly who causing mortality and intensive care , and compared the clinical efficacy of the anti-interlukien6 receptors monoclonal tocilizumab and its converters for managing COVID-19 would be included.

2.3 Criteria that excluded

The followings were excluded: cases reports; single arm study, duplicates, researches that not reported outcome results for tocilizumab in COVID-19; data that were not compare the outcomes for tocilizumab with control or placebo group, pharmaco-kinetic study, and in-vitro studies.



Figure (2): Flow diagram of study selection

3. The results

Data collected from 74 articles has been screened by study work. A total of 40 were selected yielding 10 studies for both qualitative and quantitative analysis. The systematic review of 10 occurred studies in different countries included A total of 5521 patients (10 studies; n= 1219 received TCZ; Male (67.6%), and median age of 60.9 yrs.; n=4411 control patients received conventional therapy, Male (70.09%), and median age of 63.6 yrs. Outcomes was improved with TCZ (28.3 % mortality rate) compared with 40.98% in control patients as shown in table (1):

Table 1: Characteristics of included studies

		TCZ group			Control group		
Reference	Study cite	Median age (yr.)	Sex	Mortality rate (TCZ)%	Median age (yr)	sex	Mortality rate (control)%
Gupta et al. (2021)[30]	**USA**	58	Male 299 Female 134	125/433 (28.9%)	62	Male: 2464 Female:146	1419\3495 (40.6%)
Abeer et al. (2021)[31]	**Saudi**	57	male gender 51 Female 11	16/62 (25.8%)	52	Male :72 Female :14	53/86 (61.6%)
Van den Eynde et al. (2021)[32]	**Spain**	61	male gender 16 Female 5	7\21 (33.3%)	73	Male :27 Female :11	17\38 (44.7%)
Rodríguez-Bano et al. (2021)[33]	**Spain**	66	male: 64 female:24	10\88 (11.4%)	65	Male 149 Female 42	40\151 (25.6%)
Ruiz-Antora´n et al. (2021)[34]	Spain	65	male: 184 female: 84	45\268 (16.8%)	71	Male 140 Female 98	75\238 (31.5%)
Alaa el al. (2021)[35]	**Egyptian**	60	Male: 26 Female: 20	32/46 (69.56%)	64	Male 36 Female 27	33/63 (52.4%)
Francisco López-Medrano et al.(2021)[36]	**Spain**	74	Male: 4 Female gender 35	18/80 (22.5%)	78	Male 102 Female79	79/181 (43.6%)
Öztürk etal.(2021)[37]	**Turkish**	47	Male 10 Female 33	8/43 (18.6%)	49	Male 10 Female 34	12/44 (27.3%)
Yojana Gokhale et al. (2021)[38]	**Indian**	53	Male 107 Female 44	79\151 (52.3%)	55	Male 69 Female 49	74\118 (62.7%)
Burlacu et al. (2021)[39]	**French**	68	Male 23 Female 4	5/27 (18.5%)	67	Male 23 Female 4	6/27 (22%)
Total		60.9	Male 825 (67.6%) Female 394 (32.3%)	345/1219 (28.3%)	63.6	Male 3092 (70.09%) Female 1319 (29.9%)	1808/4411 (40.98%)

4. Discussion

COVID-19 spread quickly to the world from china. COVID-19's causal agent, Middle East respiratory disorder coronavirus 2, has a severe form (SARS-CoV-2), presented complications for critical care doctors. Cytokine storms, which can occur in up to 25% of COVID-19 patients and have been linked to death, are one of the most dangerous circumstances connected with the virus [17]. Coronavirus disease 2019 (COVID19) patients may experience significant respiratory distress, which is considered to be caused by cytokine release. Increased pro-inflammatory indicators have been linked to the severity of disease. When a cytokine storm is detected, tocilizumab, an interleukin6 receptor blocker, may be useful. The goal of this review was to look at the clinical results on the effectiveness by Tucilizumab in serious COVID-19 infection. Total mortality in both the tucilizumab treated and control groups (treatment groups without TCZ) was 28.3 percent and 40.98 percent, respectively, in the 10 existing experimental trials released from January 2021. Seven research reported that taking TCZ reduced death rates; whereas three studies revealed that it had no effect [35,37,39]. A high population study in the United States found that in critically ill COVID-19 patients treated with tocilizumab in the first two days of ICU admission had a lower risk of in-hospital mortality than those whose treatment did not include early tocilizumab use. However, an unmeasured confounding could skew the results, necessitating more research from randomized trials. However, a research by Francisco López (2021) found that using TCZ in combination with dexamethasone and other antiviral medication was related with reduced fatality rates than using corticosteroids and conventional therapy alone. The TCZ group would have benefited from the baseline imbalances in terms of age and comorbidities [36].

Another Spanish study found that individuals with serious COVID-19 condition which managed by tocilizumab had better prognosis than those who were not [34]. In addition, a Spanish adjusted, multicenter observational trial found that tocilizumab was linked to a lower risk of intubation or death in patients with COVID-19 infection, with clinical and laboratory evidence indicating a hyper-inflammatory state. Tocilizumab was used in 88 patients, whereas combo therapy was used in 151 patients. The primary endpoint was reached in 10 (11.4%) and 40 (25.6%) of the participants, respectively. In this study, tocilizumab was linked to a higher fatality rate. This study suggested that TCZ could be beneficial in COVID-19 patients with a hyper-inflammatory condition and that randomized trials in these situations should be prioritized [33]. The study by *Van den Eynde et al.* in 2021 found that using an immune modulator medication was linked to lower deaths in hospitalized patients in severe COVID-19 condition. In-hospital

mortality rates are reduced the most when TCZ is used alone or in combination with a steroid. The tocilizumab group had a mortality rate of 33.3 percent (n = 7) while the corticosteroids group had a mortality rate of 44.7 percent (n = 17) [32]

The efficacy of TCZ was tested in serious COVID-19 infectious group in Saudi research. Overall, fatal rate in the tucilizumab group was significantly lower, while the duration of the hospital staying significantly longer than control group [31]. A study in Egypt compared the survival outcomes of severe covid-19 patients taken high dosing of Dexamethasone against tucilizumab. As comparison to those who got tucizumab, patients who received steroid treatment had a higher rate of survival [35] . *Lan et al*. did a meta-analysis of tucilizumab for severe COVID-19 infected individuals in concordance with these findings [40]

According to *ztürk et al. (2021),* 27.3% patients were died in the conventional patients group and 18.6% patients passed in the Tucilizumab treated group, indicating a modest contrast between patient groups that was of no consequence in lowering mortality rates in this study [37]. In a research conducted in India, serious COVID-19 pneumonia cases with continuous hypoxia after taking a single dose of tocilizuma had a much lower death rate compared to those who receiving only the standard care management. Mortality rates in severe pneumonia that treated with TCZ was reported to be 52.3 percent, compared to 62.7 percent in controls [38].

A research paper in French assessed the effectiveness of tocilizumab vs standard care therapy alone in severe COVID-19 cases compared to control group. 27 severe COVID-19 cases who received tucilizumab were compared to 27 severe COVID-19 patients not receiving it. In terms of mortality, Tucilizumab did not enhance the clinical status of patients once evaluated by comparing to the treatment group that received standard care (18.5 percent vs 22 percent). Surprisingly, older age, male gender, obesity, and chronic respiratory diseases have all been associated to a greater chance of death in patients with COVID-19. In contrast to control group, TCZ-treated patients are more likely to experience side effects like secondary infection, pneumonia, septicemia, fungemia, and pulmonary thrombotic disease [41].

Some studies have advantages, such as multicenter involvement and improved analysis for observational research. On the other hand, significant flaws in these analyses were discovered, such as the observational study's control of confounders being insufficient despite all efforts.

Tucilizumab has no standard treatment regimen in the trials included because of differences in gender, age, dosing schedule (the number of doses and their strength), route and administration time to get the best therapeutic outcomes.

5.Conclusions

This evaluation was based on reports concerning the clinical information's of the Interlukin 6 suppresser tocilizumab in serious conditions with COVID-19 infectious patients, with the goal of improving the efficacy of lowering the pandemic disease's mortality rate. We can conclude from the findings of this study that administering tucilizumab to patients with severe illness of COVID-19 minimises the chance of death.

6. Recommendations

Several criteria would improve the evaluation of tucilizumab as a treatment alternative for immunological dysregulating complication linked with COVID-19 in light of this review analysis

1) Results from previously undisclosed clinical trials should be made public.

2) Evaluating the effects of tucilizumab and comparing them to those of other IL-6 .inhibitors like siltuximab or sarilumab.

3) Measure the immunological biomarkers and mediators levels in human and animal model trials infected with SARS –CoV2 associated with tucilizumab administration to complete the extra metabolic parameters.

4) The synergistic effect of tucilzumab with antiviral medicines like remdesivir should be .investigated

5) Tucilizumab is not licensed for usage outside of clinical trials until the full results of these trials are published.

References

1. Bogoch, II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med. 2020;27
2. Gollapalle L Viswanatha1* , CH K V L S N Anjana Male2 , Hanumanthappa Shylaja3 .1; Efficacy and safety of tocilizumab in the management of COVID- 19: A systematic review and meta-analysis of observational studies medRxiv; February 23, 2021
3. Hoiland RL, Stukas S, Cooper J. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome. Br J Haematol. 2020;190: e150–e154
4. Shimizu M. Clinical Features of Cytokine Storm Syndrome. In: Cron RQ, Behrens EMC eds. Cytokine Storm Syndrome. Cham, Springer International Publishing, 2019; pp. 31–41.
5. Hojyo, S., Uchida, M., Tanaka, K. et al. How COVID-19 induces cytokine storm with high mortality. InflammRegener. 2020;40: 37
6. Hassan S, Sheikh FN, Jamal S, Ezeh JK, Akhtar A (2020) Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment. Cureus 12: e7355.
7. Singhal T (2020) A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 87: 281 – 286
8. Huamán-Saavedra JJ, The COVID-19 pandemicInterim Recommendations for US Community Facilities with Suspected/Confirmed Coronavirus Disease 2019". U.S. Centers for Disease Control and Prevention (CDC). . Trujillo Medical Journal 15: 53 11 February 2020. Retrieved 4 April 2020
9. Fehr AR, Perlman S. Coronaviruses: an overview of their replication andpatho-genesis. Methods Mol Biol. 2015;1282:223_
10. Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgentprevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21:730_8
11. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spikeprotein is a class I virus fusion protein:structural and functional characterization of the fusion core complex. J Virol. 2003; 77:8801–11.

12. V.S. Raj, H. Mou, S.L. Smits, D.H. Dekkers, M.A. Müller,R. Dijkman, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC Nature, 495 (7440) (2013), pp. 251-25.
13. N. Wang, X. Shi, L. Jiang, S. Zhang, D. Wang, P. Tong, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 Cell Res, 23 (8) (2013), p. 986
14. X. Xu, P. Chen, J. Wang, J. Feng, H. Zhou, X. Li, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission Science China LifeSciences, 63 (3) (2020), pp. 457-460.
15. Ning Zhang , Tao Xie , Wei Ning , Rongxin He , Bin Zhu ,and Ying MaoThe Severity of COVID-19 and Its Determinants: A Systematic Review and Meta-Analysis in China ; Sustainability 2021, 13, 5305
16. Blanco-Melo D, Nilsson-Payant B, Liu W, Uhl S, Hoagland D, Moller R, Jordan T, Oishi K, Panis M, Sachs D, Wang T, Schwatz R, Lim J, Albrecht R, tenOever B. 2020. Imbalance host response to sARS-CoV-2 drives development of COVID-19. Cell 181(5):1036–1045.
17. Cao X. COVID-19:0 immunopathology and its implications for therapy. Nature (2020), 20(5):269–270
18. Zhang C, Wu Z, Li J, Zhao H, Wang G. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. International Journal of Antimicrobial Agents (2020),55(5):105954
19. Gubernatorova E, Gorshkova E, Polinova A, Drutskaya MS. . IL-6: relevance for y immunopathology of SARS-CoV-2. Cytokine and Growth Factor (2020) Reviews 53:13–24
20. Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, Mencarini J, Caporale R, Peruzzi B, Antonelli A, Trotta M, Zammarchi L, Ciani L, Gori L, Lazzeri C, Matucci A, Vultaggio A, Rossi O, Almerigogna F, Parronchi P, Fontanari P, Lavorini F, Peris A, Rossolini G, Baroloni A, Romaganani S, Liotta F, Annunziato F, Cosmi L. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. (2020) Journal of Clinical Investigation 130(9):4694
21. Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034
22. Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A, Hohmann E, Chu H, Luetkemeyer A, Kline S, Castilla D, Finberg R, Dierberg K, Tapson V, Hsieh L, Patterson T, Paredes R, Sweeney D, Short W, Touloumi G, Lye D, Ohmagari N, Oh M, Ruiz-Palacios G, Benfield T, Fatkenheuer G, Kortepeter M, Atmar R, Creech B, Lundgren J, Babiker A, Pett S, Neaton J, Burgess T, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane H.

Remdesivir for the treatment of Covid-19: preliminary report. The New England Journal of Medicine. 2020.

23. Hernandez A, Roman Y, Pasupuleti V, Barboza J, White C.. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Annals of Internal Medicine (2020), 173(4):287–296
24. Russell C, Millar J, Baillie J. Clinical evidence does not support corticosteroid treatment for2019-nCoV lung injury.(2020) Lancet 395(10223):473–475
25. Mukhtar H. Ahmed1 & Arez Hassan: Dexamethasone for the Treatment of Coronavirus Disease (COVID-19) SN Comprehensive Clinical Medicine (2020) 2:2637–2646
26. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, Jammal T, Walzer T, Francois B, Seve P. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. (2020), Autoimmunity Reviews 19(7):102567
27. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez L, Borca M. The role of interleukin 6 during viral infections. Frontiers in Microbiology (2019), 10:e0005757
28. Jones G, Sebba A, Gu J, Lo wenstein MB, Calvo A, Gomez-Reino JJ, et al.. "Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study". Annals of the Rheumatic Diseases.2010; 69 (1): 88–96.
29. Dinnendahl, V; Fricke, U, eds. (2010). Arzneistoff-Profile (in German). 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag.(2010) ISBN 978-3-7741-9846-3
30. Gupta S, Wang W, Hayek SS, STOP-COVID Investigators, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41
31. Abeer Al-Baadania Nazik Eltayeba Eid Alsufyania Salma Albahranib, Shareefah Basheric, HawraAlbayatd, Enas Batubarac, Sulafa Balloold,; Efficacy of Tocilizumab in Patients with Severe COVID-19: Survival and Clinical Outcomes, S1876-0341(21)00150-7 (2021)
32. Van den Eynde E, Gasch O, Oliva J, Prieto E, Calzado S, Gomila A, et al. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infectious Diseases. 2021:1-12
33. Rodríguez-Baño J, Pachón J, Carratalà J, Ryan P, Jarrín I, Yllescas M, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyper inflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology and Infection. 2021;27 (2):244-52.

34. Ruiz-Antorán B, Sancho-López A, Torres F, Moreno-Torres V, de Pablo-López I, García-López P, et al. Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, multicenter, cohort study. Infectious diseases and therapy. 2021;10(1):347-62.
35. Alaa Rashad, Sherif Mousa, Hanaa Nafady-Hego, Asmaa Nafady & Hamed Elgendy ;Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab, Scientific Reports (2021) volume 11, Article number: 8816
36. Francisco López-Medrano 1, María Asunción Pérez-Jacoiste Asín 2, Mario Fernández-Ruiz 2, Octavio Carretero 2, Antonio Lalueza 3, Guillermo Maestro de la Calle 3, José Manuel Caro 4, Cristina de la Calle 3, Mercedes Catalán 5, Rocío García-García 6, Joaquín Martínez-López 7, Julia Origüen 8, Mar Ripoll 3, Rafael San Juan 9, Hernando Trujillo et al; Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study; Int J Infect Dis. 2021 Apr; 105:487-494
37. Öztürk , S. M. Türk , D. Karataş , Ü. Erkorkmaz , K. Özmen Süner, H. Dheir, E. Güçlü, E. Gönüllü, O. Karabay . TOCILIZUMAB DID NOT REDUCE MORTALITY IN SEVERE COVID-19 PATIENTS BUT CAUSED THROMBOCYTOSIS. Scientific Abstracts. 2021-eular.3667
38. Yojana Gokhale, Rakshita Mehta, Prerna Bhavsar; Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India; BMC Infectious Diseases (2021) volume 21, Article number: 241 .
39. Burlacu, Ruxandra MDa; London, Jonathan MDb; Fleury, Audrey MDc; Sené, Thomas MDd; Diallo, Abdourahmane MDe; Meyssonnier, Vanina MDb; Zeller, Valérie MDb; Galland, Joris MDa; Huscenot, Tessa MDa; Rubenstein, Emma MDa; Trouiller, Pierre MDf; Amathieu, Roland MDg; Kutter, Johannes MDh; Blondeel, David MDi; Lejour, Gabriel MDg; Mouly, Stéphane MDa; Lidove, Olivier MDb; Wladimir, Mauhin MDb; Sène, Damien MDa,; No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients Results from a retrospective controlled multicenter study; Medicine: May 28, 2021 - Volume 100 - Issue 21 - p e26023
40. Lan, S. H. et al. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int. J. Antimicrob. (2020) Agents. 23, 106103 .
41. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv 2020. 2020.05.066